Meeting
2021 ASCO Annual Meeting
Twenty-one-gene recurrence score (RS) in germline (g)CHEK2 mutation-associated versus sporadic breast cancers (BC): A multi-site case-control study.
Authors
Anosheh Afghahi
University of Colorado, Aurora, CO
Anosheh Afghahi , Sydney Marsh , Alyse Winchester , Dexiang Gao , Hannah Parris , Lisen Axell , Leif W. Ellisen , Erin Wysong Hofstatter , Allison W. Kurian , Marie Wood , Dana Zakalik , Carol-Ann Mullin , Jennifer Lee Caswell-Jin , Virginia F. Borges , Nadine M. Tung
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Prevention, Risk Reduction, and Hereditary Cancer
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Cancer Genetics
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 10531)
DOI
10.1200/JCO.2021.39.15_suppl.10531
Abstract #
10531
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Twenty-one gene recurrence scores in individuals with breast cancer associated with CHEK2 and ATM germline pathogenic variants.
First Author: Payal Deepak Shah
Poster
2023 ASCO Annual Meeting
Integrated clinical, pathologic, and genetic data in a racially diverse hereditary breast cancer cohort.
First Author: Kenna Noel Koehler
Poster
2022 ASCO Annual Meeting
DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib.
First Author: Severine Guiu Lahaye
Poster
2021 ASCO Annual Meeting
Breast cancer ER, PR, and HER2 expression variance by germline cancer predisposition genes.
First Author: Grace Wei